Literature DB >> 28070748

Application of guidelines for aminoglycosides use in French hospitals in 2013-2014.

J Robert1,2,3, Y Péan4, S Alfandari5, J-P Bru6, J-P Bedos7, C Rabaud8, R Gauzit9.   

Abstract

In 2011, the French Agency for Safety of Health Products issued guidelines underlining the principles of proper aminoglycosides' use. The aim of the survey was to evaluate adherence to these guidelines two years after their issue. Characteristics of patients receiving aminoglycosides were recorded by voluntary facilities during a 3-month survey in 2013-2014. The modalities of aminoglycosides treatment were analysed by comparison with the French guidelines. A total of 3,323 patients were included by 176 facilities. Patients were mainly hospitalized in medical wards (33.0%), and treated for urinary-tract infections (24.7%). Compliance regarding the clinical indication and the daily aminoglycosides dose was observed in 65.2% and 62.9% of the cases, respectively. A 30-min once-daily IV administration was recorded in 62.5% of the cases. Aminoglycosides treatment duration was appropriate (≤5 days) for 93.6% of the patients. When considering the four criteria together, 23.2% of the patients had a treatment regimen aligned with the guidelines. Requests for measurements of peak and trough AG serum concentrations matched the guidelines in 24.9% and 67.4% of the cases, respectively. Two years after guidelines issue, aminoglycosides use remains unsatisfactory in French health-care facilities. Efforts should be made for guidelines promotion, especially regarding the issue of underdosing.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28070748     DOI: 10.1007/s10096-016-2892-5

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  22 in total

Review 1.  Why don't physicians follow clinical practice guidelines? A framework for improvement.

Authors:  M D Cabana; C S Rand; N R Powe; A W Wu; M H Wilson; P A Abboud; H R Rubin
Journal:  JAMA       Date:  1999-10-20       Impact factor: 56.272

Review 2.  Implementing practice guidelines for appropriate antimicrobial usage: a systematic review.

Authors:  P A Gross; D Pujat
Journal:  Med Care       Date:  2001-08       Impact factor: 2.983

3.  Update on good use of injectable aminoglycosides, gentamycin, tobramycin, netilmycin, amikacin. Pharmacological properties, indications, dosage, and mode of administration, treatment monitoring.

Authors: 
Journal:  Med Mal Infect       Date:  2012-07-07       Impact factor: 2.152

Review 4.  International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases.

Authors:  Kalpana Gupta; Thomas M Hooton; Kurt G Naber; Björn Wullt; Richard Colgan; Loren G Miller; Gregory J Moran; Lindsay E Nicolle; Raul Raz; Anthony J Schaeffer; David E Soper
Journal:  Clin Infect Dis       Date:  2011-03-01       Impact factor: 9.079

5.  Simplified estimation of aminoglycoside pharmacokinetics in underweight and obese adult patients.

Authors:  Manjunath P Pai; Anne N Nafziger; Joseph S Bertino
Journal:  Antimicrob Agents Chemother       Date:  2011-06-13       Impact factor: 5.191

6.  Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America.

Authors:  Tamar F Barlam; Sara E Cosgrove; Lilian M Abbo; Conan MacDougall; Audrey N Schuetz; Edward J Septimus; Arjun Srinivasan; Timothy H Dellit; Yngve T Falck-Ytter; Neil O Fishman; Cindy W Hamilton; Timothy C Jenkins; Pamela A Lipsett; Preeti N Malani; Larissa S May; Gregory J Moran; Melinda M Neuhauser; Jason G Newland; Christopher A Ohl; Matthew H Samore; Susan K Seo; Kavita K Trivedi
Journal:  Clin Infect Dis       Date:  2016-04-13       Impact factor: 9.079

Review 7.  Once daily aminoglycoside therapy. Is it less toxic than multiple daily doses and how should it be monitored?

Authors:  M L Barclay; C M Kirkpatrick; E J Begg
Journal:  Clin Pharmacokinet       Date:  1999-02       Impact factor: 6.447

8.  Eight years' experience of an extended-interval dosing protocol for gentamicin in neonates.

Authors:  Evan J Begg; Jane W A Vella-Brincat; Barbara Robertshawe; Mark J McMurtrie; Carl M J Kirkpatrick; Brian Darlow
Journal:  J Antimicrob Chemother       Date:  2009-03-19       Impact factor: 5.790

9.  Aminoglycosides use in patients over 75 years old.

Authors:  Thibaut Fraisse; Claudine Gras Aygon; Marc Paccalin; Virginie Vitrat; Benoit De Wazieres; Veronique Baudoux; Catherine Lechiche; Aurelie Vicens; Albert Sotto; Leonardo Pagani; Jacques Gaillat; Emmanuel Forestier; Gaëtan Gavazzi
Journal:  Age Ageing       Date:  2014-03-02       Impact factor: 10.668

10.  Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis.

Authors:  Sheryl A Zelenitsky; Godfrey K M Harding; Siyao Sun; Kiran Ubhi; Robert E Ariano
Journal:  J Antimicrob Chemother       Date:  2003-09-01       Impact factor: 5.790

View more
  2 in total

1.  Evaluation of aminoglycosides utilization in intensive care units of a teaching hospital in southern Iran.

Authors:  Afsaneh Vazin; Mahtabalsadat Mirjalili; Sara Asadi
Journal:  Pharm Pract (Granada)       Date:  2019-09-17

Review 2.  Antibiotic selection in the treatment of acute invasive infections by Pseudomonas aeruginosa: Guidelines by the Spanish Society of Chemotherapy.

Authors:  J Mensa; J Barberán; A Soriano; P Llinares; F Marco; R Cantón; G Bou; J González Del Castillo; E Maseda; J R Azanza; J Pasquau; C García-Vidal; J M Reguera; D Sousa; J Gómez; M Montejo; M Borges; A Torres; F Alvarez-Lerma; M Salavert; R Zaragoza; A Oliver
Journal:  Rev Esp Quimioter       Date:  2018-02-23       Impact factor: 1.553

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.